OBSOLETE: Levodopa-unresponsive juvenile parkinsonism

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:352504
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Levodopa-unresponsive juvenile parkinsonism is a term that was previously used to describe a form of parkinsonism that begins in childhood or adolescence and does not improve with levodopa treatment. Parkinsonism refers to a group of movement problems that include tremor (shaking), stiffness in the muscles, slowness of movement, and difficulty with balance and walking. In most forms of Parkinson disease, the medication levodopa helps relieve symptoms, but in this particular form, patients do not experience meaningful improvement with levodopa therapy. This distinction is important because it suggests a different underlying cause compared to typical Parkinson disease. This entry is now considered obsolete in the Orphanet classification system, meaning it has been retired or reclassified. Patients who were previously diagnosed under this label may now fall under more specific genetic or clinical diagnoses, such as certain forms of neurodegeneration with brain iron accumulation, juvenile-onset dystonia-parkinsonism, or other rare genetic parkinsonian syndromes. If you or a family member received this diagnosis, it is strongly recommended to seek updated genetic testing and evaluation by a movement disorder specialist, as advances in genetic testing have allowed for more precise diagnoses. A more specific diagnosis can open the door to better-targeted treatments, clinical trials, and support resources. The treatment landscape for levodopa-unresponsive parkinsonism is challenging. Since levodopa does not help, doctors focus on other medications and supportive therapies such as physical therapy, occupational therapy, and speech therapy to manage symptoms and maintain quality of life.

Also known as:

Key symptoms:

Muscle stiffness or rigiditySlowness of movementTremor or shakingDifficulty walking or unsteady gaitBalance problems and frequent fallsDifficulty with fine motor tasks like writingMuscle cramping or abnormal postures (dystonia)Speech difficultiesSwallowing problemsReduced facial expressionFatigue and low energySleep disturbancesMood changes such as depression or anxiety

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Juvenile

Begins in the teen years

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Mar 2026CARBIDOPA, LEVODOPA, AND ENTACAPONE: New indication approved
FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Levodopa-unresponsive juvenile parkinsonism at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Levodopa-unresponsive juvenile parkinsonism community →

No specialists are currently listed for OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Levodopa-unresponsive juvenile parkinsonismForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.

Start the conversation →

Latest news about OBSOLETE: Levodopa-unresponsive juvenile parkinsonism

No recent news articles for OBSOLETE: Levodopa-unresponsive juvenile parkinsonism.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has genetic testing been done to identify the specific cause of my parkinsonism, and should it be updated with newer tests?,Since levodopa doesn't work, what other medications or treatments might help my symptoms?,Am I a candidate for deep brain stimulation or any other surgical treatments?,Are there any clinical trials I might be eligible for?,How quickly is this condition likely to progress in my case?,What therapies (physical, occupational, speech) should I be receiving regularly?,Should my family members be tested for the same genetic condition?

Common questions about OBSOLETE: Levodopa-unresponsive juvenile parkinsonism

What is OBSOLETE: Levodopa-unresponsive juvenile parkinsonism?

Levodopa-unresponsive juvenile parkinsonism is a term that was previously used to describe a form of parkinsonism that begins in childhood or adolescence and does not improve with levodopa treatment. Parkinsonism refers to a group of movement problems that include tremor (shaking), stiffness in the muscles, slowness of movement, and difficulty with balance and walking. In most forms of Parkinson disease, the medication levodopa helps relieve symptoms, but in this particular form, patients do not experience meaningful improvement with levodopa therapy. This distinction is important because it s

At what age does OBSOLETE: Levodopa-unresponsive juvenile parkinsonism typically begin?

Typical onset of OBSOLETE: Levodopa-unresponsive juvenile parkinsonism is juvenile. Age of onset can vary across affected individuals.